Breaking News, Collaborations & Alliances

Baxter, Chatham in Hemophilia Pact

To collaborate on next-gen gene therapy technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Baxter International has entered into an exclusive global agreement with Chatham Therapeutics, an affiliate of Asklepios BioPharmaceutical (AskBio), for the development and commercialization of potential treatments for hemophilia B using Chatham’s gene therapy technology. Baxter paid $25 million upfront for the development and advancement of the program through early clinical trials, and may make additional payments based on certain development and commercial milestones. Baxter will use Chatha...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters